StockData
Innoviva, Inc. logo

Innoviva, Inc. (INVA) stock

INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)

Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –

Innoviva total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Innoviva's total debt was $258.82M at Sep 30, 2026. For fiscal 2025 it was $257.73M, down 42.5% from the year before. Over ten years it grew -9.9% a year on average. The highest annual figure on record is $733.13M in fiscal 2015.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$257.73M-42.5%
FY2024Dec 31, 2024$448.34M+0.5%
FY2023Dec 31, 2023$446.23M-17.4%
FY2022Dec 31, 2022$540.37M+36.9%
FY2021Dec 31, 2021$394.65M+2.4%
FY2020Dec 31, 2020$385.52M+2.2%
FY2019Dec 31, 2019$377.12M-1.5%
FY2018Dec 31, 2018$382.86M-33.3%
FY2017Dec 31, 2017$574.36M-19.8%
FY2016Dec 31, 2016$716.09M-2.3%
FY2015Dec 31, 2015$733.13M+1.0%
FY2014Dec 31, 2014$725.64M+152.4%
FY2013Dec 31, 2013$287.50M+416566.7%
FY2011Dec 31, 2011$69.00K-74.9%
FY2010Dec 31, 2010$275.00K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$258.82M+0.6%
Q2 FY2026Jun 30, 2026$258.45M-42.4%
Q1 FY2026Mar 31, 2026$258.10M-42.5%
Q4 FY2025Dec 31, 2025$257.73M-42.5%
Q3 FY2025Sep 30, 2025$257.38M-42.5%
Q2 FY2025Jun 30, 2025$448.92M+0.4%
Q1 FY2025Mar 31, 2025$448.89M+0.5%
Q4 FY2024Dec 31, 2024$448.34M+0.5%
Q3 FY2024Sep 30, 2024$447.82M+0.5%
Q2 FY2024Jun 30, 2024$447.28M+0.5%
Q1 FY2024Mar 31, 2024$446.76M+0.5%
Q4 FY2023Dec 31, 2023$446.23M-17.4%
Q3 FY2023Sep 30, 2023$445.72M-17.4%
Q2 FY2023Jun 30, 2023$445.20M-17.4%
Q1 FY2023Mar 31, 2023$444.69M-17.5%
Q4 FY2022Dec 31, 2022$540.37M+36.9%
Q3 FY2022Sep 30, 2022$539.81M+37.6%
Q2 FY2022Jun 30, 2022$539.25M+38.3%
Q1 FY2022Mar 31, 2022$538.75M+38.9%
Q4 FY2021Dec 31, 2021$394.65M+2.4%
Q3 FY2021Sep 30, 2021$392.30M+2.3%
Q2 FY2021Jun 30, 2021$389.99M+2.3%
Q1 FY2021Mar 31, 2021$387.73M+2.3%
Q4 FY2020Dec 31, 2020$385.52M+2.2%
Q3 FY2020Sep 30, 2020$383.35M-1.4%
Q2 FY2020Jun 30, 2020$381.23M-1.4%
Q1 FY2020Mar 31, 2020$379.15M-1.5%
Q4 FY2019Dec 31, 2019$377.12M-1.5%
Q3 FY2019Sep 30, 2019$388.64M+2.0%
Q2 FY2019Jun 30, 2019$386.68M-20.5%
Q1 FY2019Mar 31, 2019$384.74M-20.6%
Q4 FY2018Dec 31, 2018$382.86M-33.3%
Q3 FY2018Sep 30, 2018$381.00M-34.1%
Q2 FY2018Jun 30, 2018$486.53M-25.6%
Q1 FY2018Mar 31, 2018$484.59M-31.0%
Q4 FY2017Dec 31, 2017$574.36M-19.8%
Q3 FY2017Sep 30, 2017$578.45M–
Q2 FY2017Jun 30, 2017$653.89M–
Q1 FY2017Mar 31, 2017$702.33M–
Q4 FY2016Dec 31, 2016$716.09M–

More Innoviva figures

See a number that looks wrong?